|
Predictive factors for prolonged response to olaparib as maintenance therapy in ovarian cancer patients with BRCA mutations. |
| |
Sana Intidhar Labidi-Galy |
Consulting or Advisory Role - AstraZeneca |
Travel, Accommodations, Expenses - Amgen |
| |
Thibault De La Motte Rouge |
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Novartis |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Novartis; Pfizer; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
Isabelle Laure Ray-Coquard |
Honoraria - AstraZeneca; PharmaMar; Roche |
Consulting or Advisory Role - Abbvie; Amgen; Pfizer |